4D Molecular Stock Target Set at $36 by H.C. Wainwright
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowH.C. Wainwright has reiterated a Buy rating on 4D Molecular Therapies (FDMT), setting a target price of $36. This reflects the firm’s confidence in the company's growth prospects and product pipeline. The reiteration of the Buy rating suggests a positive outlook that could support stock performance. A target price above the current market price may attract investor interest and influence trading decisions.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
